Morgan, Ann
Gupta, Rikisha Shah
George, Peter M.
Quint, Jennifer K.
Article History
Received: 27 March 2023
Accepted: 5 July 2023
First Online: 11 July 2023
Declarations
:
: The protocol for this research was approved by an external review committee for the research data governance group (RDG); for the Medicines and Healthcare products Regulatory Agency (MHRA) Database Research (protocol number: 20_000068), and the approved protocol is available upon request to the corresponding author. Generic ethical approval for observational research using CPRD with approval from RDG was granted by a Health Research Authority (HRA) Research Ethics Committee (East Midlands Derby, REC reference number: 05/MRE04/87) and informed consent was waived. All data analysis was performed in accordance with the Declaration of Helsinki. There was no experimentation or tissue sample analysis, only de-identified data analysis. As per all data analyses undertaken using CPRD, there was no individual level patient consent.
: Not applicable.
: RG is a current employee of Gilead Sciences, outside the submitted work. JKQ has received grants from The Health Foundation, MRC, GSK, Bayer, BI, British Lung Foundation, IQVIA, Chiesi AZ, Insmed and Asthma UK. JKQ has received personal fees for advisory board participation or speaking fees from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Bayer and Insmed. PMG has received grants from the MRC, Boehringer Ingelheim and Roche Pharmaceuticals and personal fees from Boehringer Ingelheim, Roche Pharmaceuticals, Teva, Cippla, AZ and Brainomix. AM has nothing to disclose.